Research graph
References from A phase <scp>IIa</scp> study of the anti‐ <scp>PD</scp> ‐ <scp>L1</scp> antibody avelumab in relapsed/refractory <scp>PTCL</scp> : The <scp>AVAIL</scp> ‐T trial. Local targets link to admitted publications; unresolved targets remain external evidence.
CHOP versus GEM‐P in previously untreated patients with peripheral T‐cell lymphoma (CHEMO‐T): a phase 2, multicentre, randomised, open‐label trial
10.1016/s2352-3026(18)30039-5 · 2018 · External reference
Survival of patients with peripheral T‐cell lymphoma after first relapse or progression: spectrum of disease and rare long‐term survivors
10.1200/jco.2012.44.7524 · 2013 · External reference
SHP‐1 and SHP‐2 associate with immunoreceptor tyrosine‐based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation
10.4049/jimmunol.173.2.945 · 2004 · External reference
Safety, activity, and immune correlates of anti‐PD‐1 antibody in cancer
10.1056/nejmoa1200690 · 2012 · External reference
Safety and activity of anti‐PD‐L1 antibody in patients with advanced cancer
10.1056/nejmoa1200694 · 2012 · External reference
PD‐1 regulates germinal center B cell survival and the formation and affinity of long‐lived plasma cells
10.1038/ni.1877 · 2010 · External reference
PD‐1 controls follicular T helper cell positioning and function
10.1016/j.immuni.2018.06.012 · 2018 · External reference
The receptor PD‐1 controls follicular regulatory T cells in the lymph nodes and blood
10.1038/ni.2496 · 2013 · External reference
Bright PD‐1 expression by flow cytometry is a powerful tool for diagnosis and monitoring of angioimmunoblastic T‐cell lymphoma
10.1038/s41408-020-0301-x · 2020 · External reference
Germinal‐center T‐helper‐cell markers PD‐1 and CXCL13 are both expressed by neoplastic cells in angioimmunoblastic T‐cell lymphoma
10.1309/ajcp62wrkerpxdrt · 2009 · External reference
Expression of follicular helper T cell markers in nodal peripheral T cell lymphomas: a tissue microarray analysis of 162 cases
10.1136/jcp.2010.084459 · 2011 · External reference
Peripheral T‐cell lymphoma with follicular T‐cell markers
10.1097/pas.0b013e31817f123e · 2008 · External reference
Treating relapsed/refractory mature T‐ and NK‐cell neoplasms with tislelizumab: a multicenter open‐label phase 2 study
10.1182/bloodadvances.2022009575 · 2023 · External reference
Phase II study of the PD‐1 inhibitor Pembrolizumab for the treatment of relapsed or refractory mature T‐cell lymphoma
10.1016/j.clml.2019.03.022 · 2019 · External reference
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open‐label phase 2 study (Gxplore‐002)
10.1186/s13045-021-01033-1 · 2021 · External reference
Nivolumab in patients with relapsed or refractory peripheral T‐cell lymphoma: modest activity and cases of hyperprogression
10.1136/jitc-2022-004984 · 2022 · External reference
B7‐H1 (PD‐L1, CD274) suppresses host immunity in T‐cell lymphoproliferative disorders
10.1182/blood-2009-04-216671 · 2009 · External reference
Antibody‐dependent cellular cytotoxicity activity of a novel anti‐PD‐L1 antibody Avelumab (MSB0010718C) on human tumor cells
10.1158/2326-6066.cir-15-0059 · 2015 · External reference
Multiple mutations at exon 2 of RHOA detected in plasma from patients with peripheral T‐cell lymphoma
10.1182/bloodadvances.2019001075 · 2020 · External reference
CD38‐mediated immunosuppression as a mechanism of tumor cell escape from PD‐1/PD‐L1 blockade
10.1158/2159-8290.cd-17-1033 · 2018 · External reference
Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T‐cell lymphomas
10.1073/pnas.1608839114 · 2017 · External reference
PD‐1 is a haploinsufficient suppressor of T cell lymphomagenesis
10.1038/nature24649 · 2017 · External reference
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T‐cell lymphoma (ORACLE): an open‐label randomised, phase 3 study
10.1016/s2352-3026(24)00102-9 · 2024 · External reference
First‐line immunotherapy with anti‐PD‐1 antibody for extranodal NK/T‐cell lymphoma: a retrospective study
10.1111/bjh.18957 · 2023 · External reference
Human inherited PD‐L1 deficiency is clinically and immunologically less severe than PD‐1 deficiency
2024 · External reference
High‐dimensional and single‐cell transcriptome analysis of the tumor microenvironment in angioimmunoblastic T cell lymphoma (AITL)
10.1038/s41375-021-01321-2 · 2022 · External reference
Clinical predictive value of naïve and memory T cells in advanced NSCLC
10.3389/fimmu.2022.996348 · 2022 · External reference
Integrated clinical and genomic evaluation of guadecitabine (SGI‐110) in peripheral T‐cell lymphoma
10.1038/s41375-022-01571-8 · 2022 · External reference
Frontline chemoimmunotherapy with nivolumab and dose‐adjusted EPOCH in peripheral T‐cell lymphoma: a phase 1 trial
10.1182/bloodadvances.2023011526 · 2024 · External reference
Whole‐genome CRISPR screening identifies molecular mechanisms of PD‐L1 expression in adult T‐cell leukemia/lymphoma
10.1182/blood.2023021423 · 2024 · External reference
Phase II study of the PD‐1 inhibitor Pembrolizumab for the treatment of relapsed or refractory mature T‐cell lymphoma
10.1016/j.clml.2019.03.022 · ExternalCitation · doi-reference
PD‐1 controls follicular T helper cell positioning and function
10.1016/j.immuni.2018.06.012 · ExternalCitation · doi-reference
CHOP versus GEM‐P in previously untreated patients with peripheral T‐cell lymphoma (CHEMO‐T): a phase 2, multicentre, randomised, open‐label trial
10.1016/s2352-3026(18)30039-5 · ExternalCitation · doi-reference
Oral azacitidine compared with standard therapy in patients with relapsed or refractory follicular helper T‐cell lymphoma (ORACLE): an open‐label randomised, phase 3 study
10.1016/s2352-3026(24)00102-9 · ExternalCitation · doi-reference
PD‐1 is a haploinsufficient suppressor of T cell lymphomagenesis
10.1038/nature24649 · ExternalCitation · doi-reference
PD‐1 regulates germinal center B cell survival and the formation and affinity of long‐lived plasma cells
10.1038/ni.1877 · ExternalCitation · doi-reference
The receptor PD‐1 controls follicular regulatory T cells in the lymph nodes and blood
10.1038/ni.2496 · ExternalCitation · doi-reference
High‐dimensional and single‐cell transcriptome analysis of the tumor microenvironment in angioimmunoblastic T cell lymphoma (AITL)
10.1038/s41375-021-01321-2 · ExternalCitation · doi-reference
Integrated clinical and genomic evaluation of guadecitabine (SGI‐110) in peripheral T‐cell lymphoma
10.1038/s41375-022-01571-8 · ExternalCitation · doi-reference
Bright PD‐1 expression by flow cytometry is a powerful tool for diagnosis and monitoring of angioimmunoblastic T‐cell lymphoma
10.1038/s41408-020-0301-x · ExternalCitation · doi-reference
Safety, activity, and immune correlates of anti‐PD‐1 antibody in cancer
10.1056/nejmoa1200690 · ExternalCitation · doi-reference
Safety and activity of anti‐PD‐L1 antibody in patients with advanced cancer
10.1056/nejmoa1200694 · ExternalCitation · doi-reference
Activating mutations and translocations in the guanine exchange factor VAV1 in peripheral T‐cell lymphomas
10.1073/pnas.1608839114 · ExternalCitation · doi-reference
Peripheral T‐cell lymphoma with follicular T‐cell markers
10.1097/pas.0b013e31817f123e · ExternalCitation · doi-reference
First‐line immunotherapy with anti‐PD‐1 antibody for extranodal NK/T‐cell lymphoma: a retrospective study
10.1111/bjh.18957 · ExternalCitation · doi-reference
Expression of follicular helper T cell markers in nodal peripheral T cell lymphomas: a tissue microarray analysis of 162 cases
10.1136/jcp.2010.084459 · ExternalCitation · doi-reference
Nivolumab in patients with relapsed or refractory peripheral T‐cell lymphoma: modest activity and cases of hyperprogression
10.1136/jitc-2022-004984 · ExternalCitation · doi-reference
CD38‐mediated immunosuppression as a mechanism of tumor cell escape from PD‐1/PD‐L1 blockade
10.1158/2159-8290.cd-17-1033 · ExternalCitation · doi-reference
Antibody‐dependent cellular cytotoxicity activity of a novel anti‐PD‐L1 antibody Avelumab (MSB0010718C) on human tumor cells
10.1158/2326-6066.cir-15-0059 · ExternalCitation · doi-reference
B7‐H1 (PD‐L1, CD274) suppresses host immunity in T‐cell lymphoproliferative disorders
10.1182/blood-2009-04-216671 · ExternalCitation · doi-reference
Whole‐genome CRISPR screening identifies molecular mechanisms of PD‐L1 expression in adult T‐cell leukemia/lymphoma
10.1182/blood.2023021423 · ExternalCitation · doi-reference
Multiple mutations at exon 2 of RHOA detected in plasma from patients with peripheral T‐cell lymphoma
10.1182/bloodadvances.2019001075 · ExternalCitation · doi-reference
Treating relapsed/refractory mature T‐ and NK‐cell neoplasms with tislelizumab: a multicenter open‐label phase 2 study
10.1182/bloodadvances.2022009575 · ExternalCitation · doi-reference
Frontline chemoimmunotherapy with nivolumab and dose‐adjusted EPOCH in peripheral T‐cell lymphoma: a phase 1 trial
10.1182/bloodadvances.2023011526 · ExternalCitation · doi-reference
Efficacy and safety of geptanolimab (GB226) for relapsed or refractory peripheral T cell lymphoma: an open‐label phase 2 study (Gxplore‐002)
10.1186/s13045-021-01033-1 · ExternalCitation · doi-reference
Survival of patients with peripheral T‐cell lymphoma after first relapse or progression: spectrum of disease and rare long‐term survivors
10.1200/jco.2012.44.7524 · ExternalCitation · doi-reference
Germinal‐center T‐helper‐cell markers PD‐1 and CXCL13 are both expressed by neoplastic cells in angioimmunoblastic T‐cell lymphoma
10.1309/ajcp62wrkerpxdrt · ExternalCitation · doi-reference
Clinical predictive value of naïve and memory T cells in advanced NSCLC
10.3389/fimmu.2022.996348 · ExternalCitation · doi-reference
SHP‐1 and SHP‐2 associate with immunoreceptor tyrosine‐based switch motif of programmed death 1 upon primary human T cell stimulation, but only receptor ligation prevents T cell activation
10.4049/jimmunol.173.2.945 · ExternalCitation · doi-reference
